Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06435000 · ClinicalTrials.gov registry record
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
A clinical trial of Stargardt Disease and Stargardt's Disease, sponsored by Splice Bio.
- Recruiting
- Registry status
- 75
- Enrollment target
- 20
- Study locations
NCT06435000 is a study of Stargardt Disease and Stargardt's Disease that is actively recruiting participants, run by Splice Bio. The registered enrollment target is 75 participants, below the 87-participant average among 16 other Stargardt Disease trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT06435000, a study of Stargardt Disease and Stargardt's Disease, is actively recruiting participants, sponsored by Splice Bio.
- RECRUITING
- Registry status
- 75 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an Observational Study to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene This is a multicenter study which will enroll approximately 75 subjects
Conditions Studied
Study Locations (20)
Other
- Universitätsklinikum Bonn, Klinik für Augenheilkunde - Bonn
- University Eye Hospital Tübingen - Tübingen
- Leeds Teaching Hospitals NHS Trust - Leeds
- University of Manchester - The Old St Mary's Hospital - Manchester
- Oxford Eye Hospital - Oxford
Florida
- Vitreo Retinal Associates - Gainesville
- Bascom Palmer Eye Institute - Miami
New York
- Columbia University Medical Center - New York
- CUIMC/Edward S. Harkness Eye Institute - New York
California
- Shiley Eye Institute - San Diego
Colorado
- UCHealth Sue Anschutz-Rodgers Eye Center - Aurora
Georgia
- Emory University - Atlanta
Maryland
- Wilmer Eye Institute, Johns Hopkins University MD 21287 - Baltimore
Massachusetts
- Massachusetts Eye and Ear Infirmary - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2024-03-29 |
| Est. Completion | 2027-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06435000
The ClinicalTrials.gov registry entry for NCT06435000 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 87-participant average among 16 other Stargardt Disease trials with a reported enrollment target (14% lower). The listed sponsor is Splice Bio, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Stargardt Disease appearing as the primary indexed condition, and to 0 interventions.
NCT06435000 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT06435000 about?
NCT06435000 is a clinical study titled "An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene". This is an Observational Study to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene This is a multicenter study which will enroll approximately 75 subjects
What is the current status of trial NCT06435000?
This trial is currently recruiting. The enrollment target is 75 participants. The study started on 2024-03-29. Estimated completion is 2027-02.
What conditions does trial NCT06435000 study?
This clinical trial studies the following conditions: Stargardt Disease, Stargardt's Disease, STGD1, Stargardt.
Who is sponsoring clinical trial NCT06435000?
This trial is sponsored by Splice Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06435000 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stargardt Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Observational Study in Children and Adults With Stargardt Disease
RECRUITING
-
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
RECRUITING · Phase 1
-
A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
RECRUITING
-
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
RECRUITING
-
A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
RECRUITING · Phase 2
-
Stem Cell Ophthalmology Treatment Study II
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.